uniQure (NASDAQ:QURE) Reaches New 52-Week High Following Analyst Upgrade

uniQure (NASDAQ:QURE) hit a new 52-week high on Monday after Stifel Nicolaus raised their price target on the stock from $12.00 to $32.00. Stifel Nicolaus currently has a buy rating on the stock. uniQure traded as high as $17.63 and last traded at $17.54, with a volume of 1889446 shares. The stock had previously closed at $15.40.

A number of other research analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of uniQure in a report on Tuesday, December 10th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday, December 11th. Cantor Fitzgerald raised their target price on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. Finally, Leerink Partners boosted their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.13.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.74% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in QURE. abrdn plc boosted its position in uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the period. Franklin Resources Inc. bought a new stake in shares of uniQure during the 3rd quarter worth about $7,360,000. Point72 Asset Management L.P. grew its stake in uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares during the last quarter. FMR LLC raised its holdings in uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after acquiring an additional 346,274 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in uniQure during the second quarter worth approximately $815,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Trading Down 5.4 %

The business has a fifty day moving average price of $7.28 and a 200-day moving average price of $6.47. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market cap of $802.31 million, a P/E ratio of -3.27 and a beta of 0.89.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. On average, analysts forecast that uniQure will post -3.82 earnings per share for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.